{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:11:55Z","timestamp":1778022715143,"version":"3.51.4"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol Surg B Skull Base"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sinonasal cancers are malignant neoplasms arising from the nasal cavity and paranasal sinuses, including squamous cell carcinoma (SCC), adenocarcinoma, and undifferentiated carcinoma. Due to their rarity, comprehensive genomic data remain limited. Treatments include surgery, radiation, and chemotherapy, with ongoing trials investigating agents like cetuximab, cisplatin, and Tazemetostat.<\/jats:p>\n                  <jats:p>We analyzed sinonasal cancer cases from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database via cBioPortal (v16.1-public, accessed July 22, 2024). Common gene mutations, correlations, and mutual exclusivities were assessed using statistical analyses with false discovery rate correction.<\/jats:p>\n                  <jats:p>Of 2,595 head and neck cancer samples, 122 (4.7%) were sinonasal carcinoma: 70 (57.4%) SCC, 31 (25.4%) undifferentiated carcinoma, and 21 (17.2%) adenocarcinomas. The most frequent mutations were TP53 (tumor protein 53; 40%), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; 14%), KMT2D (lysine methyltransferase 2D; 11%), and CDKN2A (cyclin-dependent kinase inhibitor 2A; 9%). Subtype-specific mutations included IDH2 (isocitrate dehydrogenase; 230%) in undifferentiated carcinoma and FAT1 (15%) in adenocarcinoma. TP53 frequently co-occurred with PRKDC (protein kinase, DNA-activated, catalytic subunit; p\u2009=\u20090.020), while KMT2D co-occurred with PIK3CA (p\u2009=\u20090.018).<\/jats:p>\n                  <jats:p>TP53, PIK3CA, and KMT2D mutations are prevalent in sinonasal carcinoma, highlighting potential targets for therapy. Tazemetostat, targeting KMT2D-related DNA (deoxyribonucleic acid) methylation, and cetuximab, targeting the PIK3CA signaling cascade, may offer therapeutic benefits. Further research on mutation-specific therapies could improve treatment strategies.<\/jats:p>","DOI":"10.1055\/a-2639-5790","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T19:07:15Z","timestamp":1750273635000},"page":"337-344","source":"Crossref","is-referenced-by-count":1,"title":["Comprehensive Genomic Profiling of Sinonasal Carcinomas: Identification of Common Mutations and Potential Targets for Therapy"],"prefix":"10.1055","volume":"87","author":[{"given":"Gabriel","family":"Bitar","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, Arizona, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6403-502X","authenticated-orcid":false,"given":"Beau","family":"Hsia","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, Arizona, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Alshaka","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, Arizona, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien A.","family":"Valencia","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Florida, Jacksonville, Florida, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Naval Medical Center San Diego, San Diego, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Children's Hospital of Orange County, Orange, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Crawford","sequence":"additional","affiliation":[{"name":"Children's Hospital Orange County, University of California Irvine, Department of Pediatrics and Neurology, Orange, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Levy","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of California San Diego-Rady Children's Hospital, San Diego, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Polster","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Chicago, Chicago, Illinois, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Pediatric Otolaryngology, Rady Children's Hospital, San Diego, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/lary.25465","article-title":"Sinonasal malignancies: a population-based analysis of site-specific incidence and survival","volume":"125","author":"R Dutta","year":"2015","journal-title":"Laryngoscope"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.3390\/curroncol28040222","article-title":"Malignant sinonasal tumors: update on histological and clinical management","volume":"28","author":"A Bracigliano","year":"2021","journal-title":"Curr Oncol"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/archotol.133.2.131","article-title":"Survival rates of sinonasal squamous cell carcinoma with the new AJCC staging system","volume":"133","author":"C H Lee","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"16","key":"ref4","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1002\/cncr.30686","article-title":"A comprehensive comparative analysis of treatment modalities for sinonasal malignancies","volume":"123","author":"T P Robin","year":"2017","journal-title":"Cancer"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.18632\/oncotarget.13798","article-title":"Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma","volume":"8","author":"W Gong","year":"2017","journal-title":"Oncotarget"},{"issue":"05","key":"ref6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30145-1","article-title":"Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study","volume":"19","author":"A Italiano","year":"2018","journal-title":"Lancet Oncol"},{"issue":"06","key":"ref7","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/annonc\/mdv109","article-title":"Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing","volume":"26","author":"C H Chung","year":"2015","journal-title":"Ann Oncol"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"issue":"23","key":"ref9","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"I de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"269","key":"ref10","first-page":"pl1","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"J Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"E Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"ref12","first-page":"9","article-title":"Profile of TP53 gene mutations in sinonasal cancer","volume":"686","author":"R Holmila","year":"2010","journal-title":"Mutat Res"},{"issue":"09","key":"ref13","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1078-0432.CCR-21-4316","article-title":"Association of TP53 and CDKN2A mutation profile with tumor mutation burden in head and neck cancer","volume":"28","author":"A Y Deneka","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1758-3284-3-20","article-title":"Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study","volume":"3","author":"J K Peltonen","year":"2011","journal-title":"Head Neck Oncol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/s41598-020-80242-z","article-title":"Next-generation sequencing for identification of actionable gene mutations in intestinal-type sinonasal adenocarcinoma","volume":"11","author":"P S\u00e1nchez-Fern\u00e1ndez","year":"2021","journal-title":"Sci Rep"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.oraloncology.2012.12.011","article-title":"Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma","volume":"49","author":"P Bossi","year":"2013","journal-title":"Oral Oncol"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"a006120","DOI":"10.1101\/mcs.a006120","article-title":"PIK3CA mutation in a case of CTNNB1-mutant sinonasal glomangiopericytoma","volume":"8","author":"C S Hong","year":"2022","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"14","key":"ref18","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1200\/JCO.21.01648","article-title":"Phase II study of copanlisib in patients with tumors with PIK3CA mutations: results from the NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocol Z1F","volume":"40","author":"S Damodaran","year":"2022","journal-title":"J Clin Oncol"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0194599811399559","article-title":"Cetuximab therapy for head and neck squamous cell carcinoma: a systematic review of the data","volume":"144","author":"T D Reeves","year":"2011","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4132\/jptm.2022.01.04","article-title":"Frequency of PIK3CA mutations in different subsites of head and neck squamous cell carcinoma in southern Thailand","volume":"56","author":"A Dechaphunkul","year":"2022","journal-title":"J Pathol Transl Med"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"7148","DOI":"10.1038\/s41467-022-34815-3","article-title":"DNA methylation-based classification of sinonasal tumors","volume":"13","author":"P Jurmeister","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.5858\/arpa.2018-0224-RS","article-title":"High-grade sinonasal carcinoma: classification through molecular profiling","volume":"143","author":"J Guilmette","year":"2019","journal-title":"Arch Pathol Lab Med"}],"container-title":["Journal of Neurological Surgery Part B: Skull Base"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2639-5790.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:32:43Z","timestamp":1778020363000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2639-5790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":22,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2639-5790","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2193-6331","2193-634X"],"issn-type":[{"value":"2193-6331","type":"print"},{"value":"2193-634X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,18]]},"published":{"date-parts":[[2025,6,18]]}}}